TruWealth Advisors LLC Purchases 1,437 Shares of Eli Lilly and Company $LLY

TruWealth Advisors LLC lifted its position in Eli Lilly and Company (NYSE:LLY) by 4.3% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 34,898 shares of the company’s stock after purchasing an additional 1,437 shares during the quarter. Eli Lilly and Company accounts for 1.3% of TruWealth Advisors LLC’s portfolio, making the stock its 20th largest position. TruWealth Advisors LLC’s holdings in Eli Lilly and Company were worth $26,626,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. Lazard Freres Gestion S.A.S. grew its stake in Eli Lilly and Company by 114.3% during the second quarter. Lazard Freres Gestion S.A.S. now owns 77,295 shares of the company’s stock worth $60,253,000 after buying an additional 41,222 shares during the last quarter. Precedent Wealth Partners LLC boosted its holdings in shares of Eli Lilly and Company by 15.3% in the 2nd quarter. Precedent Wealth Partners LLC now owns 294 shares of the company’s stock worth $229,000 after acquiring an additional 39 shares in the last quarter. Central Pacific Bank Trust Division grew its position in Eli Lilly and Company by 25.8% during the 3rd quarter. Central Pacific Bank Trust Division now owns 8,990 shares of the company’s stock worth $6,859,000 after acquiring an additional 1,843 shares during the last quarter. Capital Advisors Inc. OK increased its holdings in Eli Lilly and Company by 6.8% during the 2nd quarter. Capital Advisors Inc. OK now owns 6,747 shares of the company’s stock valued at $5,260,000 after purchasing an additional 429 shares in the last quarter. Finally, Family CFO Inc bought a new position in Eli Lilly and Company in the 2nd quarter valued at $54,000. 82.53% of the stock is owned by institutional investors.

Eli Lilly and Company Stock Down 0.7%

Shares of NYSE LLY opened at $1,054.69 on Wednesday. The firm has a market capitalization of $997.08 billion, a PE ratio of 51.60, a price-to-earnings-growth ratio of 1.18 and a beta of 0.37. The company has a current ratio of 1.55, a quick ratio of 1.24 and a debt-to-equity ratio of 1.71. Eli Lilly and Company has a 1 year low of $623.78 and a 1 year high of $1,111.99. The firm’s 50-day moving average is $948.02 and its 200-day moving average is $824.99.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings results on Thursday, October 30th. The company reported $7.02 earnings per share for the quarter, topping analysts’ consensus estimates of $6.42 by $0.60. Eli Lilly and Company had a net margin of 30.99% and a return on equity of 109.52%. The business had revenue of $17.60 billion during the quarter, compared to the consensus estimate of $16.09 billion. During the same period in the previous year, the firm posted $1.18 earnings per share. Eli Lilly and Company’s revenue for the quarter was up 53.9% compared to the same quarter last year. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. Equities analysts expect that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, March 10th. Stockholders of record on Friday, February 13th will be paid a $1.73 dividend. This is an increase from Eli Lilly and Company’s previous quarterly dividend of $1.50. The ex-dividend date of this dividend is Friday, February 13th. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.7%. Eli Lilly and Company’s dividend payout ratio (DPR) is currently 29.35%.

Analysts Set New Price Targets

Several analysts have recently commented on LLY shares. CICC Research increased their target price on Eli Lilly and Company from $801.00 to $1,060.00 and gave the stock a “neutral” rating in a report on Thursday, November 13th. The Goldman Sachs Group upped their price target on shares of Eli Lilly and Company from $951.00 to $1,145.00 and gave the stock a “buy” rating in a research report on Monday. Truist Financial increased their price objective on shares of Eli Lilly and Company from $1,038.00 to $1,182.00 and gave the stock a “buy” rating in a report on Wednesday, November 19th. Sanford C. Bernstein boosted their target price on shares of Eli Lilly and Company from $1,100.00 to $1,300.00 and gave the stock an “outperform” rating in a research note on Monday, November 24th. Finally, Leerink Partnrs raised shares of Eli Lilly and Company from a “hold” rating to a “strong-buy” rating in a research note on Monday, November 10th. Four investment analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and four have issued a Hold rating to the company’s stock. According to MarketBeat, Eli Lilly and Company currently has a consensus rating of “Buy” and a consensus target price of $1,141.73.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.